Legato Capital Management LLC purchased a new stake in  Haemonetics Co. (NYSE:HAE – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 3,169 shares of the medical instruments supplier’s stock, valued at approximately $249,000.

Several other large investors have also recently made changes to their positions in HAE. Wipfli Financial Advisors LLC acquired a new stake in  Haemonetics in the 3rd quarter valued at approximately $25,000.  Romano Brothers AND Company acquired a new stake in shares of  Haemonetics in the fourth quarter valued at $31,000.  Altshuler Shaham Ltd purchased a new stake in shares of  Haemonetics in the 3rd quarter valued at $59,000.  FinTrust Capital Advisors LLC acquired a new position in  Haemonetics during the 3rd quarter worth about $60,000.  Finally, Eagle Bay Advisors LLC lifted its stake in  Haemonetics by 23.6% during the 4th quarter. Eagle Bay Advisors LLC now owns 792 shares of the medical instruments supplier’s stock worth $62,000 after acquiring an additional 151 shares in the last quarter.

In other news, EVP Josep Llorens sold 2,391 shares of the business’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $90.00, for a total transaction of $215,190.00. Following the completion of the sale, the executive vice president now owns 17,234 shares in the company, valued at approximately $1,551,060. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.65% of the stock is currently owned by corporate insiders.

A number of analysts have issued reports on the stock. StockNews.com started coverage on shares of Haemonetics in a research note on Thursday, March 16th. They set a “buy” rating on the stock. Mizuho upped their target price on shares of Haemonetics from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, February 8th. Citigroup decreased their price target on shares of Haemonetics from $95.00 to $90.00 in a research report on Monday, April 3rd. Morgan Stanley boosted their price target on shares of Haemonetics from $84.00 to $88.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 8th. Finally, Barrington Research increased their price objective on Haemonetics from $94.00 to $103.00 and gave the company an “outperform” rating in a research note on Wednesday, February 8th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.17.

Haemonetics stock opened at $85.00 on Wednesday. The company has a current ratio of 3.11, a quick ratio of 1.99 and a debt-to-equity ratio of 0.98. The company has a fifty day simple moving average of $80.27 and a 200-day simple moving average of $80.99. The stock has a market cap of $4.29 billion, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 2.58 and a beta of 0.44. Haemonetics Co. has a 12-month low of $48.67 and a 12-month high of $91.39.

Haemonetics (NYSE:HAE – Get Rating) last announced its quarterly earnings results on Tuesday, February 7th. The medical instruments supplier reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.06. Haemonetics had a return on equity of 19.84% and a net margin of 8.48%. The company had revenue of $305.30 million during the quarter, compared to the consensus estimate of $300.47 million. During the same period in the previous year, the business earned $0.84 EPS. Haemonetics’s revenue for the quarter was up 17.5% on a year-over-year basis.  Equities analysts expect that  Haemonetics Co. will post 2.94 EPS for the current fiscal year.

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.